株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

PharmaPoint:乾癬−−米国での薬剤予測と市場分析

PharmaPoint: Psoriasis - US Drug Forecast and Market Analysis to 2022

発行 GlobalData 商品コード 276719
出版日 ページ情報 英文 142 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.18円で換算しております。

2016年12月31日まで 年末キャンペーン割引: GlobalData社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
PharmaPoint:乾癬−−米国での薬剤予測と市場分析 PharmaPoint: Psoriasis - US Drug Forecast and Market Analysis to 2022
出版日: 2013年05月31日 ページ情報: 英文 142 Pages
概要

当レポートでは、米国における乾癬の治療薬に関する最新の研究・開発状況と、関連市場の将来展望とを分析し、疾患の概要や治療法、市場機会とアンメットニーズ、市場規模の動向(今後10年間分)、現在発売中および治験中の主な薬剤のプロファイル、米国市場の現状と今後の方向性などの情報を盛り込んで、概略以下の構成でお届けします。

第1章 目次

第2章 イントロダクション

第3章 疾患の概要

  • 病因と病態
    • 病因
    • 病態
  • 兆候

第4章 疾患の管理

  • 治療法の概要
  • 米国
    • 診断
    • 臨床診療

第5章 競争力の評価

  • 概要
  • 競合企業の戦略的評価
  • 製品プロファイル:主要ブランド
    • Enbrel(エタネルセプト)
    • Humira(アダリムマブ)
    • Remicade (インフリシマブ)
    • Stelara(ウステキヌマブ)
    • Taclonex(カルシポトリオール水和物およびジプロピオン酸ベタメタゾン)
    • メトトレキサートナトリウム(様々なジェネリック医薬品名つき)
    • 乾癬の治療に用いられるマイナーな治療薬クラス
    • 非薬物治療

第6章 市場機会とアンメットニーズ

  • 概要
  • アンメットニーズ
    • 薬剤の安全性および有効性の向上
    • 寛解予知のためのバイオマーカー
    • 経口製剤・バイオシミラーによる、よりコスト効率的な治療法
    • 乾癬に付随する心理的要因に関する教育と処置
    • 効果的かつ生物学的/組織的な局所療法
    • 軽度の乾癬に関するより効果的な治療法(特に紫外線療法)
    • (尋常性乾癬に限らず)様々な種類の乾癬に関する医学教育
  • 市場機会
  • アンメットニーズのギャップの分析
    • 診断・治療のための予測ツール
    • 標的の特殊性
    • 生物学的/組織的な局所療法のオプション
    • 乾癬に伴う心理的問題に直面した患者の支援

第7章 パイプライン分析

  • 概要
  • 治験中の有望な薬剤
    • Brodalumab (AMG 827)
    • Secukinumab (AIN457)
    • Ixekizumab (LY2439821)
    • Tildrakizumab (MK-3222/SCH-900222)
    • Xeljanz (tofacitinib)
    • Apremilast (CC-10004)
    • 第II相のパイプライン製品
    • 第I相のパイプライン製品
    • バイオシミラーのパイプライン製品

第8章 市場の見通し

  • 米国市場
    • 予測
    • 主要動向
    • 市場の促進要因と障壁

第9章 付録

図表一覧

目次
Product Code: GDHC1106CFR

Summary

GlobalData has released its new Country report, "PharmaPoint: Psoriasis - US Drug Forecast and Market Analysis to 2022". There are no long-term effective therapies for Psoriasis (PsO), so this remains at the top of the list for unmet needs. While physicians agree that biologics are relatively safe and effective, these therapies are still lacking because of their immunosuppressant nature and lack of understanding as to their exact mechanism of action.

The US is the largest PsO market, although it does not have the highest prevalence of the disease. GlobalData estimates that the US generated approximate sales in 2012. J&J's Stelara has been impressive since launching in 2009, and claimed close the patient share compared with its company counterpart, Remicade, which only drew less in 2012. Since Stelara's cost per day is the highest of the biologics, which is three times that of Remicade, it did not take a lot of patient share to generate comfortable annual sales close in 2012.

Scope

  • Overview of Psoriasis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on the key drugs in the US including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for the top drugs in the US from 2012 to 2022.
  • Analysis of the impact of key events as well the drivers and restraints affecting the US Psoriasis market.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Psoriasis
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of drug performance
  • Obtain sales forecast for drugs from 2012 to 2022 in the US.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Symptoms

4. Disease Management

  • 4.1. Treatment Overview
  • 4.2. US
    • 4.2.1. Diagnosis
    • 4.2.2. Clinical Practice

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Strategic Competitor Assessment
  • 5.3. Product Profiles - Major Brands
    • 5.3.1. Enbrel (etanercept)
    • 5.3.2. Humira (adalimumab)
    • 5.3.3. Remicade (infliximab)
    • 5.3.4. Stelara (ustekinumab)
    • 5.3.5. Taclonex (calcipotriene hydrate and betamethasone dipropionate)
    • 5.3.6. Methotrexate Sodium (numerous generic names)
    • 5.3.7. Minor Therapeutic Drug Classes Used in Psoriasis
    • 5.3.8. Non-Pharmacological Therapy

6. Opportunity and Unmet Need

  • 6.1. Overview
  • 6.2. Unmet Needs
    • 6.2.1. Improved Drug Safety and Efficacy Profiles
    • 6.2.2. Biomarkers for Predicting Remission
    • 6.2.3. More Cost-Effective Therapies Through Oral Formulation and Biosimilars
    • 6.2.4. Education and Treatment of Psychological Factors Accompanying Psoriasis
    • 6.2.5. An Effective Biologic/Systemic Topical Therapy
    • 6.2.6. More Effective Treatment for Mild Psoriasis, Specifically UV Therapies
    • 6.2.7. Physician Education About the Different Types of Psoriasis, not Just Plaque Psoriasis
  • 6.3. Opportunities
  • 6.4. Unmet Needs Gap Analysis
    • 6.4.1. Predictive Tools for Diagnosis and Treatment
    • 6.4.2. Target Specificity
    • 6.4.3. Topical Biologic/Systemic Therapeutic Options
    • 6.4.4. Helping Patients with Psychological Issues Associated with Psoriasis

7. Pipeline Assessment

  • 7.1. Overview
  • 7.2. Promising Drugs in Clinical Development
    • 7.2.1. Brodalumab (AMG 827)
    • 7.2.2. Secukinumab (AIN457)
    • 7.2.3. Ixekizumab (LY2439821)
    • 7.2.4. Tildrakizumab (MK-3222/SCH-900222)
    • 7.2.5. Xeljanz (tofacitinib)
    • 7.2.6. Apremilast (CC-10004)
    • 7.2.7. Phase II Pipeline Products
    • 7.2.8. Phase I Pipeline Products
    • 7.2.9. Biosimilars Pipeline Products

8. Market Outlook

  • 8.1. United States
    • 8.1.1. Forecast
    • 8.1.2. Key Events
    • 8.1.3. Drivers and Barriers

9. Appendix

  • 9.1. Bibliography
  • 9.2. Abbreviations
  • 9.3. Methodology
  • 9.4. Forecasting Methodology
    • 9.4.1. Diagnosed Psoriasis Patients
    • 9.4.2. Percent Drug-Treated Patients
    • 9.4.3. Drugs Included in Each Therapeutic Class
    • 9.4.4. Launch and Patent Expiry Dates
    • 9.4.5. General Pricing Assumptions
    • 9.4.6. Individual Drug Assumptions
    • 9.4.7. Generic Erosion
    • 9.4.8. Pricing of Pipeline agents
  • 9.5. Physicians and Specialists Included in this Study
  • 9.6. Primary Research - Prescriber Survey
  • 9.7. About the Authors
    • 9.7.1. Analysts
    • 9.7.2. Global Head of Healthcare
  • 9.8. About GlobalData
  • 9.9. Disclaimer

List of Tables

  • Table 1: Immune Cells Involved in Lesions
  • Table 2: Symptoms of Psoriasis
  • Table 3: Minimal Investigative Measures Required Before Prescribing Biologics for Psoriasis
  • Table 4: Treatment Guidelines for Psoriasis
  • Table 5: Top Three Biologics Prescribed for Moderate to Severe Psoriasis by Market, 2012
  • Table 6: Leading Treatments for Psoriasis, 2013
  • Table 7: Product Profile - Enbrel
  • Table 8: Enbrel SWOT Analysis, 2013
  • Table 9: Product Profile - Humira
  • Table 10: Humira SWOT Analysis, 2013
  • Table 11: Product Profile - Remicade
  • Table 12: Efficacy Results of RESTORE1 Trial of Remicade vs. MTX at Week 26
  • Table 13: Safety Results (AEs) of RESTORE1 Trial of Remicade vs. MTX at Week 16
  • Table 14: Remicade SWOT Analysis, 2013
  • Table 15: Product Profile - Stelara
  • Table 16: Stelara SWOT Analysis, 2013
  • Table 17: Product Profile - Taclonex
  • Table 18: Taclonex SWOT Analysis, 2013
  • Table 19: Product Profile - Methotrexate
  • Table 20: Methotrexate SWOT Analysis, 2013
  • Table 21: Summary of Minor Therapeutic Drug Classes for Psoriasis, 2013
  • Table 22: Overall Unmet Needs in Psoriasis - Current Level of Attainment
  • Table 23: Clinical Unmet Needs in Psoriasis - Gap Analysis, 2013
  • Table 24: Psoriasis - Phase Pipeline, 2013
  • Table 25: Comparison of Therapeutic Classes in Development for Psoriasis, 2013
  • Table 26: Product Profile - Brodalumab
  • Table 27: Efficacy Results of Phase II Study of Brodalumab vs. Placebo at Week 12
  • Table 28: Brodalumab SWOT Analysis, 2013
  • Table 29: Product Profile - Secukinumab
  • Table 30: Secukinumab SWOT Analysis, 2013
  • Table 31: Product Profile - Ixekizumab
  • Table 32: Efficacy Results of Phase II Study of Ixekizumab vs. Placebo at Week 12
  • Table 33: Ixekizumab SWOT Analysis, 2013
  • Table 34: Product Profile - Tildrakizumab
  • Table 35: Tildrakizumab SWOT Analysis, 2013
  • Table 36: Product Profile - Xeljanz
  • Table 37: Xeljanz SWOT Analysis, 2013
  • Table 38: Product Profile - Apremilast
  • Table 39: Efficacy Results of Phase IIb Study of Apremilast vs. Placebo at Week 16
  • Table 40: Apremilast SWOT Analysis, 2013
  • Table 41: Phase II Psoriasis Pipeline, 2013
  • Table 42: Phase I Psoriasis Pipeline, 2013
  • Table 43: Biosimilars Pipeline, 2013
  • Table 44: Sales Forecasts ($) for Psoriasis in the United States, 2012-2022
  • Table 45: Key Events Impacting Sales for Psoriasis in the United States, 2012-2022
  • Table 46: Psoriasis Market in the United States - Drivers and Barriers, 2012-2022
  • Table 47: Key Launch Dates
  • Table 48: Key Patent Expiries
  • Table 49: Physicians Surveyed, By Country

List of Figures

  • Figure 1: Psoriatic Plaque on Elbow of Patient
  • Figure 2: The Three Layers of the Skin and Associated Structures
  • Figure 3: Healthy Skin Versus Psoriatic Skin
  • Figure 4: BB-UVB Therapy Guidelines, According to the AAD
  • Figure 5: NB-UVB Therapy Guidelines, According to the AAD
  • Figure 6: Competitive Assessment of Late-Stage Pipeline Agents in Psoriasis, 2012-2022
  • Figure 7: Estimated Sales of Biosimilars vs. Their Branded Counterparts in Psoriasis, 2012-2022
  • Figure 8: Sales for Psoriasis in the United States by Drug Class, 2012-2022
Back to Top